Safety and Efficacy of APD356 in the Treatment of Obesity

Eisai Inc.400 enrolled

Overview

This is a research study of an investigational drug, APD356, a novel, selective 5-HT2c receptor agonist, in clinical development as a potential treatment for obesity. The purpose of this study is to obtain a preliminary assessment of the safety and efficacy of APD356, when administered daily for 12 weeks, in obese subjects who are otherwise healthy. Subjects who are on concomitant medications for control of hypertension or blood lipids may qualify.

This is a double-blind, placebo-controlled, randomized, parallel group study. Three different doses of APD356 or placebo will be administered daily for 12 weeks, to obese, male and nonpregnant, nonlactating, female volunteers, aged 18 to 65 years. Approximately 400 subjects will be enrolled.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

400

Conditions

Obesity

Interventions

APD356DRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Healthy male or nonpregnant, nonlactating females aged 18-65 years (inclusive) * Body mass index (BMI) of 30-45 kg/m2 * Non-smoker * No concomitant medications other than hypertension medications (stable \> 90 days) and/or statins (stable \> 90 days) * No past treatment with drugs associated with the development of pulmonary hypertension or cardiac valvular insufficiency * No more than mild mitral valve regurgitation and absence of aortic valve regurgitation upon screening echocardiogram

Locations (1)

Pennington Biomedical Research Center

Baton Rouge, Louisiana, United States

Outcomes

Primary Outcomes

Change in body weight

Secondary Outcomes

Safety

Changes in waist circumference, hip circumference, and waist/hip ratio

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.